Real-World Ritlecitinib Treatment of Severe Alopecia Areata (AA) in the US: Patient Characteristics and Physician Satisfaction

This study on ritlecitinib, a JAK3/TEC family kinase inhibitor for severe alopecia areata (AA), involved 123 adults with a mean age of 37.1 years. At initiation, patients had an average scalp hair loss of 71%, with 73% experiencing worsening AA. Treatment goals included reducing hair loss (94%) and improving quality of life (41%). Ritlecitinib was the first AA treatment for 46% of patients, and hair regrowth improved with treatment duration: 49% at <3 months, 72% at 3-6 months, and 82% at >6 months. Physician satisfaction with AA control also increased over time, reaching 85% after >6 months. Despite coping improvements, many patients still faced emotional challenges. Ritlecitinib was selected for its efficacy, safety, and cost-benefit ratio, highlighting the need for sustained treatment to manage patient expectations.